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Postoperative troponin measurement as a screening tool for adverse
cardiac events in adult patients undergoing moderate or major non-cardiac
surgery
Abstract
Elevated troponin levels within three days of surgery are strongly linked to major adverse cardiac events
(MACE). However, the value of screening with troponin measurements is controversial. The extent to which
this is done in routine practice is uncertain. We examined the medical records of all patients ≥45 years of age
undergoing moderate or major non-cardiac surgery in our tertiary referral hospital over a six-month period.
We determined how many patients had a troponin (TnT) measurement recorded in the first three days
postoperatively, how many of these were abnormal, and the occurrence of MACE within 30 days. Two
thousand and two hundred patients underwent 2,577 operations that met the study criteria. A postoperative
TnT was measured after 4.5% of operations. Thirty-eight percent of patients with a recorded TnT
measurement, and 44% of those with an abnormal measurement, experienced a MACE within 30 days. The
sensitivity of an abnormal TnT to detect MACE was 86%. The specificity was low at 32% with a false positive
rate of 56%. Patients with an abnormal TnT result had an increased risk of MACE (23%). The 'number needed
to measure' to detect one patient with MACE was 4.4. In our institution, postoperative TnT levels were rarely
measured and were used as a diagnostic rather than as a screening tool. The high false positive rate for MACE
prediction limits its potential value as a screening tool. The test could be considered useful if it leads to further
investigation, and may be best considered as one component of a multivariate approach to cardiac risk
evaluation and diagnosis.
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Postoperative troponin measurement as a screening tool for 
adverse cardiac events in adult patients undergoing moderate 
or major non-cardiac surgery 
D. Coric*, N. A. Smith†
Summary
Elevated troponin levels within three days of surgery are strongly linked to major adverse cardiac events (MACE). However 
the value of screening with troponin measurements is controversial. The extent to which this is done in routine practice is 
uncertain. We examined the medical records of all patients ≥45 years of age undergoing moderate or major non-cardiac 
surgery in our tertiary referral hospital over a six-month period. We determined how many patients had a troponin (TnT) 
measurement recorded in the first three days postoperatively, how many of these were abnormal, and the occurrence 
of MACE within 30 days. Two thousand and two hundred patients underwent 2,577 operations that met the study 
criteria. A postoperative TnT was measured after 4.5% of operations. Thirty-eight percent of patients with a recorded TnT 
measurement, and 44% of those with an abnormal measurement, experienced a MACE within 30 days. The sensitivity of an 
abnormal TnT to detect MACE was 86%. The specificity was low at 32% with a false positive rate of 56%. Patients with an 
abnormal TnT result had an increased risk of MACE (23%). The ‘number needed to measure’ to detect one patient with MACE 
was 4.4. In our institution, postoperative TnT levels were rarely measured and were used as a diagnostic rather than as a 
screening tool. The high false positive rate for MACE prediction limits its potential value as a screening tool. The test could be 
considered useful if it leads to further investigation, and may be best considered as one component of a multivariate approach 
to cardiac risk evaluation and diagnosis.
Key Words: troponin, postoperative complications, cardiovascular diseases, perioperative medicine
Adverse cardiac events after non-cardiac surgery are 
relatively common. One in twelve patients aged 45 and 
over sustains an ischaemic heart injury after non-cardiac 
surgery, and two-thirds of these events are asymptomatic1-4. 
Symptomatic and asymptomatic myocardial infarctions 
carry a similar risk of mortality1. Cardiac causes are 
responsible for up to half of deaths occurring within 30 days 
postoperatively1,2,5. They are also associated with substantially 
increased rates of complications, prolonged hospitalisation 
and increased costs1.  
Diagnosis of postoperative myocardial ischaemia is not 
straightforward and is often performed by detection of 
raised serum troponin (TnT) levels2. The availability of high-
sensitivity fifth generation assays has further improved 
the specificity and sensitivity of this test6. Elevated TnT 
levels within three postoperative days are strongly linked 
to short- and longer-term mortality5,7. Without monitoring 
of perioperative TnT levels during the first few days after 
surgery in patients with known vascular disease or risk 
factors, the majority of myocardial infarctions and injuries 
will be undetected1. Early detection of myocardial ischaemia 
allows for rapid management and potentially improved 
postoperative outcomes1,8-10.
One previous report noted that in inpatients ≥45 years 
of age having non-cardiac surgery, the number necessary 
to screen to detect myocardial injury that would otherwise 
be missed, is only about 15 patients2. One international 
collaboration recommends routine monitoring of cardiac 
biomarkers in high-risk patients after major surgery, with TnT 
as the preferred marker11. Others have suggested that it is 
not valuable as a screening tool12. TnT measurement is not 
currently established as a standard postoperative screening 
measure.
We performed a retrospective audit to explore how TnT 
measurements were used in routine clinical practice in our 
institution. We first determined how many patients aged ≥45 
years undergoing moderate to major non-cardiac surgery 
who stayed at least one postoperative night in our tertiary 
referral hospital had a TnT measurement recorded in the first 
three days postoperatively. We then explored the utility of 
this measurement in the prediction of major adverse cardiac 
events (MACE) at 30 days postoperatively. 
Methods
This retrospective audit was registered as a quality 
improvement project with The Wollongong Hospital Clinical 
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Governance Unit (4/5/2016). We examined the electronic 
medical records of all surgical patients ≥45 years of age who 
spent at least one night in hospital postoperatively in a 
six-month study period from April to September 2016. 
Both scheduled (elective) and unscheduled (emergency) 
procedures were included. The Wollongong Hospital is an 
outer metropolitan tertiary referral centre with 500 beds. 
Approximately 12,500 operations are performed each 
year with all types of surgery excluding cardiothoracic and 
complex paediatric procedures. The electronic medical 
record includes complete information on most aspects of 
inpatient care including pathology, radiology, consultations, 
perioperative records, ward progress records and discharge 
information.
Data were extracted for all study patients who had at 
least one measurement of high-sensitivity TnT (hs-TnT) on 
postoperative days 0 to 3. We followed local New South 
Wales (NSW) pathology guidelines that defined hs-TnT 
<14.0 ng/l as normal, with 14.0 ng/l and above as abnormal. 
Electronic medical records (eMR) were accessed through 
PowerChart® (Cerner, North Sydney, NSW) and manually 
searched to obtain demographic and outcome data on each 
patient. The clinical reasoning behind the ordering of any 
individual TnT measurement was not recorded in the eMR, so 
could not be audited.
MACE within 30 days of surgery was defined according to 
previous literature to include cardiac arrest, acute coronary 
syndrome (ACS), new onset heart failure or pulmonary 
oedema, new arrhythmia, cerebrovascular accident (CVA), 
and death due to a vascular cause5,13. All deaths due to non-
vascular causes were also recorded, as were unplanned 
postoperative intensive care unit (ICU) admissions. Data were 
entered into Microsoft Excel (Microsoft® Office Professional 
Plus 2013, Redmond, WA, USA) and analyses were computed 
using IBM SPSS 24.0 (IBM, Armonk, NY, USA).
The statistical approach to determining the predictive value 
of a marker depends on the purpose of the test and the 
clinical context in which it is performed14. If the purpose of a 
test is to screen for a disease state (MACE in this situation), 
the test should have a high sensitivity so that few true cases 
are missed. If the purpose is to make a diagnosis, then a test 
should have a high degree of specificity, so that few patients 
are misclassified as having the disease. A trade-off between 
sensitivity and specificity always exists. The acceptability 
of the balance between a high sensitivity and a high false 
positive rate depends on the clinical context14. In our 
situation, a high rate of false positives would mean that more 
patients would be concerned about and investigated for 
MACE than was necessary, whereas a high false negative rate 
would suggest that a number of patients would suffer missed 
or delayed diagnosis and intervention. It has been noted that 
the best prediction model for an individual patient is likely to 
involve multiple variables rather than a single test, and that 
to be useful, any single test should improve the predictive 
ability of established models15. 
Results
A total of 6,372 operations were performed in the six-
month study period. Of these, 2,577 operations were 
performed in 2,200 patients aged ≥45 years who stayed in 
hospital for at least one postoperative night. Of these, 116 
patients (5.3%) had at least one TnT measurement on days 
0 to 3 postoperatively. This cohort of 116 patients had a 
total of 121 operations in the study period. The 116 TnT 
measurements occurred after 4.5% of the 2,577 operations 
(Table 1).
Eighty-seven of the initial postoperative TnT levels were 
abnormal (75%), with 29 (24%) within the normal range. 
In the total of 116 patients, 44 (38%) experienced a MACE 
within 30 days of surgery (Table 2). Data from patients 
who underwent more than one operation were analysed 
in relation to the first operation. The large majority of 
MACE events (38/44, 86%) occurred in the patients with an 
abnormal TnT. The incidence of MACE in the abnormal TnT 
group was twice that of the normal TnT group (44% versus 
Table 1
Demographics of patients with troponin measurements
Overall Abnormal TnT Normal TnT
Age, mean (SD) 73.1 (11.1) 74.7 (11.2) 68.2 (9.5)








Elective 43  
(35.5%)
Emerg 62 (67.4%)







Vascular 19 (15.7%) 14 5
General 31 (25.6%) 27 4
HNENT 8 (6.6%) 8 0
Neurosurgery 6 (5.0%) 3 3
Orthopaedic 35 (28.9%) 24 11
Other  22 (18.2%) 16 6
TnT, troponin; Emerg, emergency operation; SD, standard deviation; HNENT, 
head and neck and ear, nose, and throat surgery.
Table 2
Frequencies of abnormal troponins and major adverse cardiac events
 MACE  
TnT Yes No Total
Abnormal 38 49 87
Normal 6 23 29
Total 44 72 116
TnT, troponin; MACE, major adverse cardiac event.
Troponin for postoperative cardiac screening
685
Anaesth Intensive Care 2017 | 45:6
21%). Table 3 presents the predictive statistical analysis. 
Patients with an abnormal TnT result had an increased risk 
of MACE (23%) with a number needed to measure to predict 
MACE of 4.4 patients. 
A receiver operating characteristic analysis was performed. 
This showed an area under the curve of 0.699 (95% 
confidence interval, 0.597 to 0.801). The accuracy of 
tests with areas under the curve between 0.50 and 0.70 
is generally considered as low; between 0.70 and 0.90 as 
moderate; and over 0.90 as high16. 
A total of 62 MACEs were found in 44 patients, with many 
individuals experiencing more than one type of MACE 
(Table 4). Furthermore, 20 of the 25 (80%) unplanned 
postoperative ICU admissions in the study patients were 
in those with abnormal TnT levels. Eight deaths occurred 
within 30 days of surgery in the study population. All deaths 
occurred in patients with an abnormal TnT level, and all 
occurred in patients who presented for emergency surgery. 
Discussion 
In a large cohort of patients aged ≥45 years having 
moderate or major surgery in our institution, TnT 
measurements were rarely performed. When performed, 
75% of tests were abnormal. The low frequency and high 
detection rates suggest that TnT measurements were being 
performed more as a diagnostic than as a screening tool. 
Predictive analysis suggests at best a moderate value for 
abnormal TnT as a tool to predict postoperative MACE. The 
test had a high sensitivity of 86% but its utility based on our 
results would be limited mainly by the low specificity, with 
a high false positive rate of 56% and low positive predictive 
value of 44%. 
The 116 patients in this study who had a TnT measured 
were presumably a higher risk group than the rest of the 
sample in whom measurements were not performed. We 
were unable to assess the reasoning behind TnT requests but 
postulate that they were at least to some degree performed 
according to clinical indicators at the discretion of the 
treating teams. The type of clinical findings that triggered 
a TnT measurement could not be determined. Our findings 
therefore represent the potential utility of TnT measurements 
in a group with postoperative suspicion of myocardial 
ischaemia based on other parameters. For patients without 
this clinical suspicion, the incidence of postoperative 
ischaemia is likely to be lower and the TnT test positive and 
negative predictive values are likely to be less convincing.
The high sensitivity of the test (86%) is encouraging and 
is close to that suggested for screening tools. Patients with 
a high TnT had double the incidence of MACE compared to 
those with a normal TnT level. Almost half of the patients 
with an abnormal TnT level suffered at least one type of 
MACE. Eighty percent of unplanned ICU admissions and all 
deaths occurred in the abnormal TnT group of patients. This 
approach to the data suggests that identifying a group of 
patients at higher risk may be valuable if an abnormal TnT 
level results in closer medical observation and treatment. 
The optimal treatment to improve patient outcomes after 
postoperative myocardial ischaemia is not yet established. 
Treatment options include aspirin, beta-blockers, angiotensin 
converting enzyme inhibitor drugs, statins, early reperfusion 
strategies, and more comprehensive evaluation such as 
angiography and echocardiography, but definitive outcome 
studies are awaited2,8. Lack of established treatment 
guidelines may limit the usefulness of early identification. 
Table 3
Analysis of troponin levels and major cardiac events
Index Value Interpretation 
Sensitivity 0.864 86% of patients with a MACE were 
correctly detected by the TnT.
Specificity 0.319 32% of patients without a MACE were 
correctly labelled by the TnT.
Positive predictive 
value 
0.437 Of those labelled by the TnT as 
“abnormal”, 44% had a MACE. 56% of 
positive TnT results were false positives.
Negative 
predictive value 
0.793 Of those labelled by the TnT as “normal”, 
79% did not have a MACE. 21% of 
negative TnT results were false negatives.
Likelihood ratio+ 1.269 A positive TnT result (i.e., labelled as 
“abnormal”) was slightly more likely in 
those who had a MACE.
Likelihood ratio- 2.343 A negative TnT result (i.e., labelled as 
“normal”) was two times as likely to have 
come from a person without a MACE.
Odds ratio 2.97 The odds of having a MACE were 3 times 
higher with an abnormal TnT.
Risk difference 0.23 Patients with a positive TnT result had an 
increased risk for MACE of 23%.
Numbers needed 
to screen
4.4 4.4 patients must be labelled by the TnT 
as “abnormal” to detect 1 patient with 
a MACE.
TnT, troponin; MACE, major adverse cardiac event.
Table 4






ACS 16 (100%) 0 16
Acute PO 8 (100%) 0 8
New CCF 1 (100%) 0 1
New arrhythmia 22 (85%) 4 (15%) 26
Cardiac arrest 5 (83%) 1 (17%) 6
CVA 4 (80%) 1 (20%) 5
Note: more than one type of MACE in an individual patient was common. 
MACE, major adverse cardiac event, TnT, troponin; ACS, acute coronary 
syndrome; PO, pulmonary oedema; CCF, congestive cardiac failure; CVA, 
cerebrovascular accident.
D. Coric et al
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In the real clinical world, aggressive treatment is unlikely 
to be initiated after a single abnormal level without 
other confirming factors such as serial measurements 
or other abnormal test results. TnT measurement may 
be best considered as one part of a multivariate risk 
prediction model, rather than as a single measure with 
a definitive binary outcome. Other potential benefits of 
early identification of abnormal TnT levels include alerting 
patients to their risk of future myocardial events, improving 
hypertension control, and taking advantage of a teachable 
moment to promote lifestyle changes, including smoking 
cessation2.
The question of whether TnT measurements should be 
performed in higher risk surgical populations as a routine 
screening tool or only as a diagnostic tool has not yet 
been conclusively answered. The most recent American 
College of Cardiology/American Heart Association Guideline 
recommends measurement of postoperative TnT levels only 
in the setting of signs or symptoms suggestive of myocardial 
ischaemia12. The current study suggests that clinical practice 
in our institution reflects this guideline. Postoperative 
screening in high-risk patients without signs or symptoms 
suggestive of myocardial ischaemia is considered to have 
uncertain value due to the absence of validated treatment 
strategies to attenuate the risk of an abnormal TnT8. 
Routine postoperative screening for directing perioperative 
management is not recommended in this guideline. 
Obtaining an electrocardiogram (ECG) was given the same 
weighting as performing TnT measurements12.
On the other hand, abnormal postoperative TnT levels 
have been found to be an independent predictive measure 
for both MACE and mortality at various timepoints from 30 
days to three years and in various surgical populations in an 
increasing number of studies5,7,17-23. Most of these studies 
report hazard ratios, odds ratios and logistic regression 
analysis as their method of risk prediction. There have been 
several recent reviews supporting routine TnT measurement 
postoperatively and the field now contains a strong body of 
evidence1,2,13. Without monitoring of perioperative TnT levels 
during the first few days after surgery in patients with known 
vascular disease or risk factors, the majority of myocardial 
infarctions and injuries will be undetected1. A troponin 
measurement, when added to other postoperative blood 
tests, currently costs A$19.69 in our institution. At this cost, 
with a number needed to measure of 4.4 patients, a decision 
to use the test as a screening tool could well be considered 
to be cost-effective and beneficial to individual patients. On 
the other hand, it could lead to unnecessary concern and 
unnecessary further investigations for many patients if not 
interpreted correctly.
The background prevalence of MACE and the definition 
of a ‘high-risk’ patient are clearly important factors in this 
discussion. Some authorities consider a background incidence 
of myocardial injury of 8% in patients aged over 45 having 
moderate or major surgery sufficient to consider the entirety 
of this group as high-risk, particularly as this is such an 
important clinical problem2. Others require the presence of 
other cardiac risk factors, or signs and symptoms, to define a 
high-risk group. Thirty-eight percent of our population with 
a measured TnT experienced a MACE. It could be reasonably 
supposed that clinical suspicion of myocardial injury selected 
a higher risk cohort amongst our patient sample. As a 
theoretical calculation, if our population in whom a TnT was 
not measured, numbering 2,084 individuals, had experienced 
a rate of MACE of the background 8% figure, then potentially 
166 patients in the unmeasured group were at risk. A broader 
use of TnT measurements may have detected more of these 
patients at an early stage. 
The decision about the manner in which to use the test 
revolves around the intended purpose, the clinical context, 
and the balance between false positives and negatives. 
One could argue clinically that a high detection rate is the 
priority, as treatment is only likely to occur after other more 
confirmatory findings and because myocardial ischaemia is a 
very important patient event. Our study suggests that almost 
half of patients with a high postoperative TnT in a high-risk 
group with clinical suspicion will have a MACE. The VISION 
study reported that inclusion of the peak TnT in the first three 
days postoperatively added incremental prognostic value to 
predict 30-day mortality compared to models not including 
TnT measurement5. The monetary cost of the test is low. 
Clinical concerns including the time and cost of investigating 
false positives need to be considered and balanced against 
the risk of missing or delaying diagnosis and intervention. 
This is a single-centre study, and although large 
numbers were included, it may not be representative of 
or generalisable to other institutions. The retrospective 
nature means that we could not influence patient events or 
outcomes in any way. Outcome timepoints of longer than 
30 days may yield further information and be even more 
relevant to patients. We did not collect detailed data on the 
vast majority of surgical patients in this period for whom a 
TnT was not measured. Therefore, we cannot comment on 
the rate of MACE in the rest of the surgical population. Other 
variables that could theoretically be important in predicting 
outcomes include preoperative factors such as presence 
of cardiovascular comorbidities and type of medications, 
intraoperative factors such as duration and blood loss, and 
postoperative factors such as level of care1. Our study was 
not designed or able to investigate the potential impact of 
such other variables, but these are important considerations 
for overall risk reduction.  
Conclusion
In conclusion, in this large pragmatic observational study, 
we investigated the actual practice of postoperative TnT 
measurement in a large tertiary referral hospital in Australia. 
Troponin for postoperative cardiac screening
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We report that in our institution, this simple and inexpensive 
measure is currently being used as a diagnostic rather 
than as a screening tool. We confirm that in the setting of 
postoperative surgical patients with a clinical suspicion of 
myocardial ischaemia, TnT measurement can identify patients 
at high risk of significantly poor outcomes, including death, 
with a number needed to measure of 4.4. Our data suggest 
that some of these patients may be missed if screening 
measurements are not performed. The cost of the test is 
low, and the cost of missing the diagnosis of postoperative 
myocardial ischaemia is high. Predictive statistical analyses 
suggest a low–moderate value of an elevated TnT to predict 
MACE in this situation. It may have some utility in a high-
risk population depending on the definition of high risk and 
the clinical context. The test could be considered useful 
as an early warning sign if it leads to further investigation 
before aggressive treatment is undertaken and therefore 
may be best considered as one component of a multivariate 
approach to cardiac risk evaluation. 
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